Tech Company Financing Transactions
Pleco Therapeutics Funding Round
Pleco Therapeutics, operating out of Nijmegen, secured $17.5 million from Hyloris Pharmaceuticals SA, Netherlands Enterprise Agency and Oost NL.
Transaction Overview
Company Name
Announced On
9/6/2022
Transaction Type
Venture Equity
Amount
$17,450,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to complete development and commercialise its novel lead Plecoid� Product, PTX-061, to improve the effectiveness of chemotherapy in patients with Acute Myeloid Leukaemia (AML).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Jonkerbosplein 52
Nijmegen, 6534 AB
NL
Nijmegen, 6534 AB
NL
Phone
Website
Email Address
Overview
Pleco Therapeutics' mission is to demonstrate the market value and therapeutic potential of our proprietary Plecoid� products through an initial focus on treatments for orphan cancers. Thereafter we can expand our scalable product platform for the treatment of other cancers as well as neurodegenerative disorders where aberrant metal patterns have been shown to play a role. Our current pre-clinical development programs focus on the development of treatments for Acute Myeloid Leukaemia (AML), a relatively rare blood cancer, and Small-Cell Lung Cancer (SCLC), an aggressive subtype of lung cancer. Both diseases carry a poor prognosis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ivo Timmermans
Browse more venture capital transactions:
Prev: 9/6/2022: Zeet venture capital transaction
Next: 9/6/2022: Cymulate venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs